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1.	  OBJECTIUS	  
-­‐  Donar	  a	  conèixer	  aquest	  glioma	  de	  grau	  IV	  i	  la	  seva	  agressivitat.	  	  
-­‐  Conèixer	  els	  mecanismes	  moleculars	  dels	  tractaments	  que	  s’han	  desenvolupat	  ﬁns	  
el	  moment	  i	  que	  estan	  en	  fase	  de	  desenvolupament	  per	  a	  tractar	  el	  GBM.	  	  
-­‐  Conèixer	  les	  probabilitats	  d’èxit	  dels	  tractaments	  en	  desenvolupament.	  	  
	  
2.	  METODOLOGIA	  
-­‐  Recerca	  bibliogràﬁca	  relacionada	  amb	  la	  malalUa.	  	  
-­‐  Selecció	  dels	  tractaments	  en	  els	  que	  es	  basarà	  el	  treball.	  	  
-­‐  Selecció	  dels	  arUcles	  més	  rellevants.	  
-­‐  Lectura	  de	  tota	  la	  informació	  recopilada.	  	  
-­‐  Síntesi	  de	  la	  informació	  i	  redacció	  del	  treball.	  	  
	  
3.	  INTRODUCCIÓ	  
	  
-­‐  El	  glioblastoma	  mulUforme	  és	  un	  tumor	  associat	  a	  les	  cèl·∙lules	  glials	  del	  SNC.	  
-­‐  Incidència:	  	  els	  gliomes	  presenten	  una	  elevada	  taxa	  de	  mortalitat	  i	  dintre	  d’aquests,	  el	  GBM	  ó	  glioma	  de	  grau	  IV	  és	  el	  que	  presenta	  una	  major	  incidència	  i	  agressivitat.	  
-­‐  Pronòs=c:	  l’esperança	  de	  vida	  mitja	  està	  al	  voltant	  dels	  14	  mesos.	  	  
-­‐  Histopatologia:	  es	  caracteritza	  per	  manifestar	  híper-­‐cromaUsme	  nuclear	  i	  unes	  propietats	  altament	  invasives	  i	  pro-­‐angiogèniques	  i	  per	  presentar	  focus	  necròUcs.	  A	  més	  a	  més,	  les	  
cèl·∙lules	  de	  glioblastoma	  també	  presenten	  una	  elevada	  resistència	  a	  l’apoptosi.	  	  
-­‐  Simptomatologia:	  els	  símptomes	  més	  freqüents	  són	  el	  dèﬁcit	  progressiu	  de	  la	  memòria,	  de	  la	  personalitat	  i	  els	  dèﬁcits	  neurològics	  depenent	  del	  lòbul	  que	  es	  vegi	  afectat.	  Però	  
aquests	  símptomes	  no	  apareixen	  ﬁns	  que	  el	  tumor	  ha	  assolit	  una	  mida	  molt	  gran	  i	  un	  alt	  grau	  d’invasió.	  	  
-­‐  Causes:	  les	  causes	  que	  provoquen	  l’aparició	  d’aquest	  tumor	  no	  estan	  clares	  ja	  que	  la	  majoria	  apareixen	  de	  forma	  esporàdica	  i	  sense	  cap	  predisposició	  genèUca	  coneguda.	  	  
-­‐  Diagnòs=c:	  per	  a	  fer	  el	  diagnòsUc	  el	  primer	  pas	  és	  realitzar	  proves	  de	  neuro-­‐imatge	  i	  posteriorment	  una	  biòpsia	  per	  a	  la	  posterior	  conﬁrmació	  patològica.	  
	  	  
8.	  CONCLUSIONS	  
-­‐  Els	  corUcoides	  i	  anUconvulsius	  milloren	  els	  símptomes	  neurològics	  però	  no	  
serveixen	  per	  destruir	  les	  cèl·∙lules	  malignes.	  	  
-­‐  Les	  cèl·∙lules	  deﬁcients	  en	  el	  gen	  d’MGMT	  són	  més	  suscepUbles	  al	  tractament	  
quimioteràpic	  amb	  temozolomida.	  	  
-­‐  És	  necessari	  trobar	  mecanismes	  per	  evitar	  la	  re-­‐aparició	  del	  tumor	  un	  cop	  es	  deixa	  
d’administrar	  la	  dieta	  cetogènica.	  	  
-­‐  Neutralitzant	  l’acUvitat	  de	  CD95	  es	  poden	  frenar	  els	  processos	  d’invasió	  de	  les	  
cèl·∙lules	  de	  GBM	  
-­‐  Els	  anUcossos	  monoclonals	  contra	  molècules	  senyalitzadores	  d’angiogènesi	  
representen	  un	  gran	  potencial	  terapèuUc.	  	  
-­‐  El	  re-­‐educament	  de	  macròfags	  per	  a	  que	  expressin	  les	  seves	  funcions	  anU-­‐tumorals	  
és	  una	  teràpia	  molt	  prometedora.	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principles of evolutionary biology and metabolic control
theory [5-7].
A high glycolytic rate with lactic acid production,
resulting largely from impaired respiratory function, is a
primary metabolic phenotype of GBM and of most can-
cers [5,6,8]. In contrast to normal brain cells, which
evolved to metabolize ketone bodies for energy when glu-
cose levels are reduced, most brain tumor cells are depen-
dent on glycolysis for survival and are unable to
metabolize ketone bodies for energy due to impaired
mitochondrial function [9]. This metabolic deficiency
allows the tumor cells to be metabolically isolated from
normal cells. A strong dependence on glucose makes the
tumor cells vulnerable to death using therapies that target
glucose metabolism. The ketogenic diet, administered in
restricted amounts, is ideally suited as a non-toxic meta-
bolic therapy fo  managing m lignan  brain cancer
because the diet naturally lowers circulating glucose lev-
els while elevating levels of ketone bodies [9-11]. The
ketogenic diet (KD) is a high fat, low carbohydrate diet
that has been used for decades as an effective therapy for
refractory seizures in children [6,12-14]. Otto and co-
workers showed that a KD supplemented with omega-3
fatty acids and medium-chain triglycerides could delay
growth of human gastric cancer cells in nude mice [15],
while Freedland and co-workers have considered the role
for low-carbohydrate KD in the management of pros ate
cancer [16]. The KD also has disease-modifying activity
against neurodegenerative disorders and protective
action against brain trauma and ischemic injuries [11,17-
19]. Hence, the ketogenic diet administered in restricted
amounts (R-KD) has potential as a non-toxic metabolic
therapy against malignant brain cancer.
While dietary restriction and re tricted ketogenic diet
therapy is effective in targeting tumor nergy metabolism
and angiogenesis in experimental animal models
[9,11,20-23], no studies have evaluated the efficacy of
restricted ketogenic diets as a therapy for older patients
with GBM. An earlier report, however, showed that the
KD was effective in managing growth and enhancing pro-
gression free survival in two children with malignant
brain tumors that were refractory to radiation and che-
motherapy [10]. In this study, we used neuro-imaging to
describe the response of a 65 year-old female GBM
patient treated with standard therapy together with a
restricted ketogenic diet.
Case Report
A 65 year-old-female was admitted to Arcispedale Santa
Maria Nuova, Reggio, Italy on December 5th, 2008 who
presented with progressive memory loss, chronic head-
aches, and nausea. The symptoms were present, off-and-
on, for about one month prior to diagnosis. Neurological
examination showed mild left superior harm and facial
paresis. The patient's family history included breast ade-
nocarcinoma (mother), and ovarian carcinoma (sister).
Past clinical history included post-pubertal headache,
hysterectomy at the age of 37 years, chronic erosive gas-
tritis and familial hypercholesterolemia controlled with
lipid-lowering medication. The patient's blood pressure
was 120/70, and within normal limits. Laboratory tests
revealed an unremarkable complete blood count. Liver
and renal functions were within normal limits. Blood bio-
chemistry was essentially normal. Prior to therapeutic
intervention, the patient's weight and height, were 64
kilograms (kg) (141 pounds) and 158 centimetres (62
inches), respectively. This height and weight related to an
approximate body mass index (BMI) of 25.6 kg/m2.
On the day of admission, the patient underwent con-
trast-enhanced (contrast media: gadoteric acid, 0.2 ml/
kg) magnetic resonance imaging (MRI), which disclosed a
large multi-centric solid necrotic tumor in the right
hemisphere (Figure 1). The tumor showed extensive infil-
tration of the right temporal pole, the insular lobe, the
frontal operculum, the putamen, and head of the caudate
nucleus. Avid contrast enhancement characterized the
tumor, which was surrounded by extensive edema. A shift
to the left of the midline structures was noted. The tumor
also compressed the right frontal horn. An electroen-
cephalogram demonstrated abnormality with a general-
ized slowing background and frequent delta bursts on the
right frontotemporal region. Anti-inflammatory steroidal
therapy (dexamethasone, 16 mg/day i.v.) and anti-epilep-
tic therapy (Topiramate, 50 mg/2×/day and Clobazam, 50
mg/day) were commenced. On December 15th, the
patient underwent right frontal temporal craniotomy
involving partial excision of the temporal pole with
incomplete debulking.
The histopathological examination disclosed the pat-
terns of GBM. Haematoxylin and eosin (H&E) analysis
showed high cellularity, prominent vascularity, as well as
areas of necrosis and hemorrhage. The tumor cells
appeared poorly differentiated, hyperchromatic, pleo-
morphic, and displayed neoplastic pseudopalisades sur-
Figure 1 MRI contrast enhanced images of a large multi-centric 
mass involving the right hemisphere pole. (A) Temporal pole, (B) 
frontal operculum, insular lobe, posterior putamen, (C)  frontal opercu-
lum, head of caudate nucleus. Note the presence of peripheral edema 
(arrows).
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include leukocytes 2.86 ×1000/mm3, erythrocytes 3.56
million/mm3, hemoglobin 10.5 g/dl, and hematocrit 32%.
The patient also developed lymphopenia 0.332 ×1000/
mm3. The conco itant treatment was terminated on
February 17th. One week later (February 24, 2009), the
p tient underwent an MRI. No evidence of either the
tumor or he sociated edema was apparent (Figure 4).
Por ncephaly was seen in the ight frontal region at the
tu or site. Ex vacuum enlargement of th  right fro tal
horn and lack of mass effect represented indirect confir-
mation of tumor regression. Restitutio ad Integrum of the
insular lobe, caudate nucleus, and putamen were noted
with only minimal damage to the blood brain barrier
(Figure 4). On March 3, the patient developed mild hypo-
proteinemia (5.1 g/dl). This was corrected by increasing
dietary protein to about 7 g/day for one month, which
returned protein levels to the normal range (6.4 gr/dl).
On April 21, the patient underwent positron emission
tomography with fluoro-deoxy-glucose (FDG-PET),
which included delayed acquisition. No evidence of
recurrent disease was detected (Figure 5). An MRI, per-
formed on July 22, was stable over the comparison time
from February 24 with no clear evidence of disease recur-
rence. At that time, the patient weighed 50 kg (110
pounds, BMI 20.0 kg/m2), was in good general health,
and had no neur logical complic tions. The patient's
Karnofsky performance status was at 100% during the
course of the diet. Caloric intake was not strictly followed
fter July 22. An MRI performed on October 9, 2008
showed tumor recurr nce. The patient was then treat d
with CPT11 (Irinotecan) and bevacizumab (Avastin)
therapy. A schematic diagram showing the clinical time
course of dietary treatments with dates of MRI and PET
is presented in Figure 6.
Discussion
In this case report we describe the management of a
highly invasive multi-centric GBM in an older patient fol-
lowing partial tumor resection and treatment with a com-
bination of standard therapy, fasting, and a R-KD. The
patient's response to this therapeutic approach was
unusual, as no prior reports have appeared to our knowl-
edge describing regression of GBM within 2.5 months
from the time of diagnosis in either younger (< 50 yrs) or
older (> 50 yrs) patients using standard radiation and
temozolomide therapy alone. Although the patient in this
study expressed hypermethylation of the MGMT gene
promoter, which enhances the therapeutic action of
temozolomide and is prognostic for increased survival
[26], no prior cases of rapid GBM regression have been
reported in patients with the MGMT hypermethylation
phenotype to our knowledge. Temozolomide is an oral
alkylating agent that damages DNA and is used as first
and second line GBM treatment [2,26,29]. Continuous
temozolomide administration depletes O6-methylgua-
nine-DNA methyltransferase, which is required for
repairing DNA damage. Based on the MRI and PET-CT
data, we speculate that the combined conventional and
metabolic approach to GBM management in this patient
enhanced early MGMT related cytotoxicity and apopto-
sis. Further studies in additional patients will be needed
to support this hypothesis.
The response of the GBM in this older female patient to
the therapeutic action of the R-KD was similar to that
reported previously in children with malignant brain
tumors treated with a medium-chain triglyceride keto-
genic diet [6,10]. High dosage steroid medication for
brain cancer patients increases gluconeogenesis and
blood glucose levels while enhancing apoptosis resistance
in tumor cells [6,30,31]. We eliminated dexamethasone
administration soon after surgery in our patient, as calo-
rie restriction and the R-KD can also target inflammation
without elevating blood glucose levels [6,30]. We consider
that dexamethasone, which induces hyperglycemia, could
Figure 4 Brain MRI taken a few days after ending the standard ra-
diotherapy plus concomitant  temozolomide therapy together 
with KD-CR protocol. No clear evidence of tumor tissue or  associated 
edema was seen. Arrow indicates porencephaly.
Figure 5 Positron emission tomography with fluoro-deoxy-glu-
cose (FDG-PET) imaging  showing no evidence of recurrent tu-
mor.
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rounding necrotic foci (Figure 2). Extensive subpial
infiltration was also noted. The histological characteris-
tics were typical for GBM (WHO grade IV) [24,25].
Methylation of the O6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter was also detectable according
to standard procedures [26]. The patient underw n  com-
puted tomography (CT) of the head during the immedi-
ate postoperative period, which showed an increasing
edema-related shift to the left of the midline structures.
During the immediate post-operative recovery period,
the patient started a self-imposed water only fast (from
December 16-17). The patient's average daily calorie
intake, prior to fasting, was about 1700-1800 kcal/day.
Blood glucose was 130 mg/dl while urine ketone levels
were undetectable. After several days of mod  food
consumption, the patient again started a water-only fast
on December 22. Blood glucose and urine ketones were
monitored using a standard glucose kit and Keto-Stick kit
(Ketur-Test®). After three days of fasting (ketosis induc-
tion period), ketones were raised to the high level of +++,
while blood glucose was reduced to 60 mg/dl. At this time
(December 24), the patient's body weight and body mass
index was 58.0 kg (127.6 lbs) and 23.23 kg/m2, respec-
tively. After the fast, a KD was administered in restricted
amounts for 14 days (December 24 to January 7, 2009).
This calorie restricted ketogenic diet (R-KD) delivered
about 600 kcal/day in total and included 20 g of the Keto-
Cal® 4:1 (fat/protein + carbohydrate) diet (SHS, Interna-
tional), 10 g medium chain triglyceride oil (MCT), 32 g
protein, and 10 g carbohydrates. The diet contained a
small amount of dietary fiber, and a total fat content of 42
g. The R-KD was supplemented with multivitamins
including the B complex and minerals to maintain nutri-
ent adequacy and to avoid metabolic abnormalities as
previously described [27].
After 14 days of the R-KD, the concomitant radiation
plus chemotherapy (temozolo ide) regimen w s initi-
ated on January 8, 2009, according to standard proce-
dures [2]. All steroidal medication was terminated a  this
time. The patient's body weight was 55 kg (121 lbs) at the
start of the standard treatment, which extended to Febru-
ary 17, 2009. On January 27, the patient developed a mild
hyperuricemia of 6.2 mg/dl (normal values: 2.4-5.7 mg/
dl). The plasma uric acid levels gradually increased reach-
ing a maximum value of 10.9 mg/dl by February 7. Tran-
sient hyperuricemia can occur following implementation
of ketogenic diets [28]. Allopurinol (100/mg/day) treat-
ment was commence  to control the uric ac d levels,
which gradually returned within normal ranges. Due to
the hyperuricemia the patient was gradually shifted to a
calorie restricted non-ketogenic diet, which also deliv-
ered a total of about 600 kcal/day. This diet maintained
low blood glucose levels and slightly elevated (++) urine
ketone levels due to the low calorie content of the diet.
The changes in circulating glucose and ketone levels dur-
ing this period are shown in Figure 3. More comprehen-
sive blood a alysis was not conducted. It is i portant to
mention that the patient did not experience hypoglyce-
mia (blood glucose levels below 45 mg/dl) at any time
during the course of fasting or ketogenic diet therapy.
During the concomitant chemotherapy, laboratory tests
revealed abnormalities in complete blood count to
Figure 2 Histopathological analysis of excised brain tumor tissue 
(H&E). A) Multiple zones of necrosis circumscribed by viable tissue (4 
×). B) Dense zone of small-cells with hyperchromatic nuclei and scant 
cytoplasm (10 ×). C) Zone of necrosis with dense pseudopalisades of 
small tumor cells at the periphery (20 ×). D) Tumor cell infiltration of the 
subpial zone of the cortex (20 ×).
Figure 3 Levels of circulating glucose (black line) and urinary ke-
tones (red line) in the patient during the period from January 8 to 
February 7, 2009. The values are within normal physiological ranges 
for people who maintain low calorie dieting [46].
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Fig.	  1:	  extretes	  de	  “Metabolic	  management	  of	  glioblastoma	  mul1forme	  using	  standard	  therapy	  
together	  with	  a	  restricted	  ketogenic	  diet:	  case	  r por.”	  (a)	  nivells	  de	  gluc sa	   n	  i	  de	  cetones	  
durant	  l’administració	  de	  la	  dieta	  cetogènica.	  (b)	  imatge	  d’MRI	  abans	  d’iniciar	  el	  tractament	  on	  
sòbserven	  edemes.	  (c)	  imatge	  d’MRI	  un	  cop	  ﬁnalitzat	  el	  tractament	  on	  ja	  no	  s’observen	  
edemes.	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expression of proinflammatory chemokines and angiogenesis
(Choi et al., 2001, 2002, 2003). Here, we report that triggering
of CD95 in gli blastomas initiates a cascade of signaling events
ultimately leading to increased migration. CD95-induced migra-
tion was first observed in cultured renal tubular cells (Jarad et al.,
2002) and has recently been reported for ovary, breast, lung, and
kidney tumor cells (Barnhart et al., 2004). In the latter study, a se-
rum gradient was added to the CD95 stimulus in order to insti-
gate and direct cell migration (Barnhart et al., 2004). Glioblas-
toma cells, on the contrary, are characterized by their invasion-
prone phenotype and do migrate in the absence of an additional
stimulus. This highly invasive behavior could be blocked in vitro,
ex vivo, and in vivo by the sole neutralization of CD95 activity, in-
dicating that CD95/CD95L contributes to the invasion-prone
phenotype of malignant glioma cells.
To invade and spread into the surrounding normal brain, tumor
cells need to digest components of the extracellular matrix
(ECM), including fibronectin, laminin, and type IV collagen. The
best characterized family of ECM-degrading enzymes is the
MMP family. MMP-9-deficient glioblastomas are less invasive
in vitro and in vivo (Rao, 2003). Glioblastomas produce signifi-
cantly higher levels of MMP-9 than do lower-grade gliomas
and normal brain tissue (Rao, 2003). Levels of MMP-9 increased
during the growth of glioblastoma cells that had been implanted
intracranially in nude mice (Sawaya et al., 1998). Furthermore,
these proteases play a role in establishing and maintaining a
microenvironment that facilitates tumor cell survival. Accord-
ingly, MMPs regulate tumor angiogenesis, and inhibition of
MMP-9 reduced capillary-like structures in mixed cultures of en-
dothelial and glioma cells (Rao, 2003). The same features hold
true for CD95L expression: (1) levels positively correlate with
the degree of malignancy (Choi et al., 2001; Frei et al., 1998;
Weller et al., 1994); (2) levels increase after intracranial inocula-
tion; (3) in human specimens of GBM, one of its preferential local-
izations is at the tumor vessels. Here we show that triggering of
CD95 greatly increases mRNA expression of MMP-9 and MMP-
2 in established glioblastoma cell lines and primary cultures, and
knockdown of MMP-2 andMMP-9 blocks CD95-inducedmigra-
tion. The promoter region of MMP-9 contains putative binding
sites for AP-1, NFkB, Sp1, and AP-2 (Sato and Seiki, 1993).
The AP-1 transcription complex plays an essential role in stimu-
lating transcription of MMP-9 (Gum et al., 1996; Sato and Seiki,
1993). c-Jun, a putative component of the AP-1 transcription
complex, has been identified as one of the most highly induced
TCF/b-catenin target genes (Mann et al., 1999; Staal et al., 2004).
Inhibition of GSK3b, as reported here, allows unphosphorylated
b-catenin to accumulate and translocate into the nucleus, where
it functions as a cofactor for transcription factors of the TCF/Lef
family (Reya and Clevers, 2005). In addition, activity of NFkBwas
concomitantly observed. Since CD95L-T4 decreases ERK activ-
ity, we believe that in T98G cells AKT regulates NFkB activity
through phosphorylation/activation of the IKK kinase, which in
turn phosphorylates IkB and allows the release of activated
NFkB (Ozes et al., 1999). Alternatively, IkB can transactivate
the p65 subunit (Madrid et al., 2000). In contrast, the induction
of motility and invasiveness previously reported for tumor cell
lines of endodermal ormesodermal origin involves ERK andCas-
pase-8 activity (Barnhart et al., 2004). Thus, activation of CD95
inducesmigration/invasion through the PI3K/AKT/GSK3b/b-cat-
enin/MMP and perhaps the PI3K/AKT/NFkB/MMP pathway.
I the past, several reports have pointed out an important role
for tyrosine phosphorylation in CD95-induced signaling (Eischen
et al., 1994; Schlottmann et al., 1996). These preliminary reports,
however, suggested that CD95-induced tyrosine phosphoryla-
tion is a prerequisite for CD95-mediated apoptosis (Eischen
et al., 1994; Gulbins et al., 1998; Schlottmann et al., 1996). Along
this line, the phosphatases SHP-1, SHP-2, and SHIP were found
to associate with CD95 to counteract survival factor-initiated
pathways (Daigle et al., 2002). Just recently, Src-induced tyro-
sine phosphorylation of Caspase-8 was found to impair CD95-
induced apoptosis (Cursi et al., 2006). We now describe associ-
ation of the Src family member Yes and p85 with CD95.
TRANCE, another TNF family member, activates PI3K through
a signaling complex involving c-Src and TRAF6 (Wong et al.,
1999). Inhibition of Fyn, another Src family member, decreased
CD95-induced migration of glioblastoma cells, although not sig-
nificantly. This can be explained by the fact that Fyn is involved
in EGFR-mediated signaling in neural cells (Stirnweiss et al.,
2006) and EGFR is a very important receptor for glioma invasion
that has been found in association with CD95 (Eberle et al.,
2005). Thus, inhibition of CD95-mediated signaling might affect
EGFR-mediated signaling and vice versa. Whether another
adaptor molecule is still missing in CD95’s PI3K-activation com-
plex (PAC) remains a subject for future studies. Alternatively, Yes
and p85 might directly interact with CD95. Accordingly, in T98G
cells, knockdown of Yes enabled CD95L-T4-induced recruit-
ment of FADD to CD95, indicating that Yes and FADD might
compete for binding to CD95. Along this line, analysis of Yes
expression levels revealed a much higher expression in T98G
than in LN18 cells. Most importantly, expression of Yes and
phosphorylation of Src family kinases was consistently found
Figure 6. Schematic Model for CD95 Signaling of Invasion in Glio-
blastoma
CD95L induces recruitment of the Src family member Yes and the p85 subunit
of PI3K (depicted here by its two subunits: p85 and p110) to CD95, thereby
activating AKT. Activated AKT phosphorylates and inactivates GSK3b, allow-
ing b-catenin translocation into the nucleus, where it induces transcription of
MMPs. This signaling pathway could be blocked by siRNA against Yes, or
MMP-2 and -9, the PI3K-specific inhibitor (Ly290059), or by lentiviral infection
with a dominant-active mutant of GSK3b (S9A).
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Fig.	  2:	  extreta	  de	  “Yes	  and	  PI3K	  bind	  CD95	  to	  signal	  invasion	  of	  glioblastoma.”	  
CD95	  senyalitza	  invasió	  de	  les	  cél·∙lules	  de	  GBM	  a	  través	  de	  YES,	  subunitat	  p85	  de	  
PI3K	  i	  de	  les	  MMPs.	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Aquests agents poden ser utilitzats per combatre el càncer reduint la sang que 
necessiten  els  tumors  per  créixer  i  estendre’s. 
El bevacizumab, aprovat per la FDA el 2009 pel tractament del glioblastoma, 
és un anticòs monoclonal que actua contra el factor de  creixement  de  l’endoteli  
vascular   (VEGF),   proteïna   senyalitzadora   implicada   en   l’angiogènesi. Aquest 
a ticòs   s’uneix   específicam nt   al      circulant   i   n’impedeix   la   seva   funció, la 
formació  de  vasos  sanguinis,  privant  al  tumor  de  l’aport  necessari  de  nutrients 
per al seu creixement i proliferació cel·lular. Els mecanismes de resistència 
incl uen la regul ció positiva de les vies alternatives proangiogèniques i un 
major  creixement    del  tumor  perivascular.  La  combinació  d’aquest  agent  amb  la  
radiació, la quimioteràpia citotòxica pot ser útil. 
En  el  28%  dels  pacients  tractats  amb  aquest  medicament  s’ha  comprovat  que  
encongeix el tumor, el 38% sobreviu almenys un any i el 43% sobreviuen 
almenys 6 mesos sense que la seva malaltia progressi. 
 
 
 
 
 
 
 
 
 
 
Les molècules  senyalitzadores  d’angiogènesi  representa  el  potencial  terapèutic  en  els  gliomes  
d’alt   grau.  VEGFR-2  és  el   primer   conductor  de   l’angiogènesi  en  aquests   tumors,  VEGF-A és 
secretat   per   la   cèl·lula   tumoral   i   inhibeix   l’acció   de   VEGFR-2. VEGFR-2 activa camins de 
senyalització que inclouen la cinasa MAP i PI2K-Akt, incrementant la permeabilitat vascular, la 
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migració de les cèl·lules endotelials i el moviment de la cèl·lula endotelial precursora. VEGF-A 
també   inhibeix   NRP1,   que   hauria   d’interaccionar   amb   VEGFR-2. Altres molècules 
proangiogèniques són les integrines αvβ3 i αvβ5. 
L’activació  de  FGFR  per  bFGF  és molt important respecte les teràpies angiogèniques. Si ANG 
½   inhibeix   el   seu   receptor   TIE2,   promou   l’angiogènesi   i   mentrestant   ANG-1inhibeix 
l’angiogènesi. Els  receptors  Notch  també  tenen  funcions  proangiogèniques   i  s’activen  després  
d’haver  inhibit  completa ent  Delta4  en  la  sup rfíci   tumoral.40 
 
 
 
 
 
 
 
 
 
Agents angiogènics en tractaments clínics per alts graus 
de gliomes 
 
Mecanismes de resistència a la teràpia angiogènica en 
gliomes  d’alt  grau.     
                                                          
40 Algunes abreviacions són: ANG – angiopoitein; bFGF – basic fibrolast growth factor; FGFR – 
fibrolast growth factor receptor; MAPK – mitogen-associated protein kinase; NRP – neuropilin; 
PDGFR – platelet-derived growth factor receptor; PI3K – phosphatidylinositol 3-kinase; VEGF-
A, vascular endothelial growth factor A; VEGFR-2 – vascular endothelial growth factor receptor 
2. 
Fig.	  3:	  extretes	  de	  “Un	  camp	  de	  batalla	   	  el	  cervell:	  glioblastoma	  mul1forme.”	  (a)	  
mo ècules	  senyalitzadores	  d’angiogènesi	  que	  representen	  un	  gran	  potencial	  terapèuUc	  en	  
els	  gli mes	  d’alt	  grau.	  (b)	  mecanismes	  de	  resistència	  a	  la	  teràpia	   nU-­‐angiogènica	  en	  
gliomes	  d’alt	  grau.	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Because CSF-1R signaling regulates mac-
rophage survival, the authors expected that 
CSF-1R inhibition would block glioma pro-
gression by depleting tumor-promoting 
TAMs. Surprisingly, they found that BLZ945 
did not deplete GBM-associated macrophages. 
Pyonteck et al.2 verified that these cells showed 
normal expression of CSF-1R and thus could 
sense the drug, but their in vitro studies 
revealed that TAMs in GBM may be protected 
from cell death by survival factors produced 
by tumor cells. How, then, can BLZ945 alter 
GBM progres ion? The auth rs first excluded 
possible BLZ945 effects on cells other than 
macrophages and then hypothesized that it 
modulates TAM activities that are involved 
with tumor progression. Indeed, macrophages 
are known to display divergent phenotypes 
according to signals that they receive from 
For the past several decades, therapeutic strat-
egies against cancer have largely focused on 
targeting malignant tumor cells. For GBM, 
unfortunately, such approaches remain largely 
unsuccessful, and most patients survive no 
longer than 1 y ar after diagnosis. Increasing 
evidence indicates that tumors develop and 
progress by co-opting see ingly normal host 
cell types that reside in or are recruited to 
tumor microenvironments1. Consequently, 
drugs that target genetically stable tumor- 
associated host cell components present inter-
esting new options in anticancer therapy.
As reported in this issue of Nature Medicine, 
Pyonteck et al.2 tested a novel drug that targets 
GBM-associated macrophages. Macrophages 
are immune cells that normally protect the 
host against infection and injury but also fre-
quently accumulate in the tumor stroma—in 
which case they are called tumor-associated 
macrophages (TAMs)—where they regulate 
tumor growth (Fig. 1a). TAMs produce fac-
tors that not only stimulate the survival, prolif-
eration, invasion and metastasis of tumor cells 
but also construct a supportive stroma by pro-
moting tumor vascularization and suppressing 
antitumor i munity3. Additionally, increased 
TAM densities correlate with shorter overall 
survival in many human cancer types, includ-
ing glioma, breast, lung and ovarian cancers 
and Hodgkin’s lymphoma4–6.
The new drug, called BLZ945, penetrates the 
brain and has high affinity and specificity for colony- 
stimulating factor 1 receptor (CSF-1R), which 
is expressed almost exclusively by macrophages 
and their progenitors7. Previous genetic and 
pharmacologic studies have shown that block-
ing CSF-1R signaling can decrease macrophage 
survival in vivo and can be used to alter TAM 
accumulation and tumor development in mouse 
mammary canc rs4,8. Pyonteck et al.2 here report 
a remarkable therapeutic ffect of BLZ945 in a 
genetic mouse model of proneural GBM. When 
given relatively early in tumor progression, the 
drug significantly increased overall mouse sur-
vival. It also induced striking tumor regression 
in mice that were treated at an advanced stage 
of isease, although additional studies will be 
needed to define how this late treatment trans-
lates into improved survival. The authors showed 
that proneural xenografts derived from patients 
with GBM responded similarly to the mouse 
tumors to CSF-1R inhibition, underscoring the 
therapeutic relevance of their findings.
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Therapeutically reeducating macrophages to treat GBM
Christopher Garris & Mikael J Pittet
Glioblastoma multiforme (GBM) is the most common type of aggressive malignant brain cancer. The current lack of  
successful therapeutics means that this disease has a dismal prognosis. However, a new study in mice offers hope for patients 
with GBM by demonstrating the efficacy of a novel drug that targets GBM-associated macrophages  (pages 1264–1272).
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Figure 1  Tumor-macrophage interactions in glioma. (a) ‘Bad’ macrophages in untreated glioblastoma 
promote tumor growth. Intact CSF-1 signaling activates trophic factor release from TAMs, which 
facilitates tumor progression. (b) Pyonteck et al.2 now show that CSF-1R inhibition with BLZ945 
mitigates TAM-provided support to tumors and may even turn these macrophages into ‘good’ cells  
that promote tumor elimination in mice modeling GBM.
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Fig.	  4:	  extreta	  de	  “Therapeu1cally	  reeduca1ng	  macrophages	  to	  treat	  GBM.”	  
Paper	  dels	  macròfags	  associats	  a	  tu ors	  en	  el	  creixement	  de	  les	  cèl·∙lules	  de	  
glioblastoma.	  (a)	  els	  macròfags	  “dolents”	  promouen	  el	  creixement	  tumoral.	  (b)	  
el	  tractament	  amb	  BLZ945	  redueix	  el	  creixement	  i	  la	  regressió	  del	  tumor.	  	  	  
